| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Giuseppe Toffoli | Q54252459 |
| Elena De Mattia | Q57023125 | ||
| Rossana Roncato | Q57207645 | ||
| Erika Cecchin | Q63887282 | ||
| Alessia Bignucolo | Q88507387 | ||
| P2093 | author name string | Giuseppe Toffoli | |
| Elena De Mattia | |||
| Erika Cecchin | |||
| Alessia Bignucolo | |||
| Rossana Roncato | |||
| P2860 | cites work | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 |
| Anti-angiogenic agents in metastatic colorectal cancer | Q26801911 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| Liquid biopsies: genotyping circulating tumor DNA | Q27010159 | ||
| BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers | Q27701633 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis | Q27852988 | ||
| Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients | Q27853121 | ||
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 | ||
| Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. | Q27853216 | ||
| Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer | Q27853224 | ||
| Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival | Q27853284 | ||
| The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer | Q27853340 | ||
| KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer | Q27853363 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Epidemiology of colorectal cancer | Q28067871 | ||
| The emerging role of immunotherapy in colorectal cancer | Q28067898 | ||
| Role of targeted therapy in metastatic colorectal cancer | Q28068817 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation | Q44846764 | ||
| A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer | Q46091563 | ||
| Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a | Q48792168 | ||
| Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy. | Q50929651 | ||
| Potential Therapy for Refractory Colon Cancer. | Q53794995 | ||
| Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. | Q54314770 | ||
| Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial | Q58614513 | ||
| Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma | Q83780031 | ||
| Gastrointestinal cancer: a step closer to combating acquired resistance in CRC | Q84458508 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
| Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial | Q33405554 | ||
| FDA Approval Summary: TAS-102. | Q33439460 | ||
| Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis | Q33599123 | ||
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. | Q34492429 | ||
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 | ||
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl | Q34669325 | ||
| Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation | Q34796781 | ||
| Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer | Q35392062 | ||
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer | Q35879064 | ||
| ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours | Q36035723 | ||
| Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program | Q36070573 | ||
| The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance | Q36141361 | ||
| Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. | Q36244599 | ||
| Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting | Q36295068 | ||
| A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. | Q36352341 | ||
| Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
| HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials | Q36671427 | ||
| A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer | Q36677966 | ||
| FDA drug approval summary: panitumumab (Vectibix). | Q36830592 | ||
| Role of heregulin in human cancer | Q36832241 | ||
| The genomic landscape of response to EGFR blockade in colorectal cancer. | Q36930106 | ||
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy | Q37175913 | ||
| Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients | Q37179483 | ||
| Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression | Q37387981 | ||
| Cancer pharmacogenomics: early promise, but concerted effort needed | Q37508335 | ||
| Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study) | Q37578321 | ||
| Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial | Q37588632 | ||
| Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial | Q37632102 | ||
| Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients | Q37636844 | ||
| New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways | Q37765767 | ||
| Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. | Q37861450 | ||
| Adjuvant treatment of colon cancer: what is next? | Q37871292 | ||
| Current opinion on optimal treatment for colorectal cancer. | Q38101612 | ||
| Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer | Q38207313 | ||
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials | Q38239192 | ||
| Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory t | Q38399406 | ||
| Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. | Q38509294 | ||
| An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. | Q38554714 | ||
| Current and advancing treatments for metastatic colorectal cancer | Q38628257 | ||
| BRAF in metastatic colorectal cancer: the future starts now. | Q38652005 | ||
| Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer | Q38764035 | ||
| Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications | Q38794338 | ||
| EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile | Q38799424 | ||
| Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. | Q38876494 | ||
| Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic | Q38882465 | ||
| Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer | Q38954045 | ||
| Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†. | Q38967826 | ||
| Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis | Q39014484 | ||
| Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer | Q39045763 | ||
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. | Q39120801 | ||
| Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q39226360 | ||
| Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers | Q39414963 | ||
| Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care | Q40022390 | ||
| MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. | Q40026210 | ||
| BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. | Q40126434 | ||
| G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab | Q40216854 | ||
| Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability | Q40850728 | ||
| Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer | Q40910995 | ||
| Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40931820 | ||
| Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer | Q41407101 | ||
| A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. | Q41483502 | ||
| A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer | Q42028936 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| targeted therapy | Q492646 | ||
| pharmacogenetics | Q1358521 | ||
| personalization | Q1000371 | ||
| pharmacogenomics | Q1152227 | ||
| precision medicine | Q17075943 | ||
| colorectal carcinoma | Q25493920 | ||
| colorectal neoplasm | Q58833976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-07-14 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment | |
| P478 | volume | 18 |
| Q91792673 | LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer |
| Q64120347 | MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer |
| Q57132503 | Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery |
| Q90731092 | Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer |
| Q89721701 | RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer |
| Q89943442 | Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1 |
| Q95642655 | Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications |
Search more.